PHASQ
PhaseBio Pharmaceuticals Inc

3,310
Loading...
Loading...
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Dover, DE.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of PhaseBio Pharmaceuticals Inc?
What is the 52-week high for PhaseBio Pharmaceuticals Inc?
What is the 52-week low for PhaseBio Pharmaceuticals Inc?
What is the 50-day moving average of PhaseBio Pharmaceuticals Inc?

Latest PHASQ News

View
No PHASQ news at the moment.

Advertisement|Remove ads.

Advertisement|Remove ads.